Yusa Togashi

Nishinomiya-hama, 6638501, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer.

Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: October 29, 2025

Current Status and Issue of Emesis and Vomiting Caused by Trastuzumab Deruxtecan

Current Status and Issue of Emesis and Vomiting Caused by Trastuzumab Deruxtecan

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: February 17, 2025

Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan.

Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan.

Journal: International journal of clinical oncology

Published: January 10, 2025

Clinical Utility of Sentinel Lymph Node Biopsy Using the Medical Imaging Projection System in Breast Cancer Patients, Including Those Following Neoadjuvant Chemotherapy.

Clinical Utility of Sentinel Lymph Node Biopsy Using the Medical Imaging Projection System in Breast Cancer Patients, Including Those Following Neoadjuvant Chemotherapy.

Journal: Anticancer research

Published: January 05, 2025

Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy.

Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy.

Journal: Breast cancer (Tokyo, Japan)

Published: November 04, 2024

Germline variants detected by multigene panel testing in patients with suspected hereditary breast cancer.

Germline variants detected by multigene panel testing in patients with suspected hereditary breast cancer.

Journal: Surgery today

Published: October 04, 2024

Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer.

Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer.

Journal: International journal of clinical oncology

Published: July 14, 2024

Long-Term Survival Outcomes and Risk Factors for Axillary and Locoregional Recurrence in Japanese Patients with Sentinel Node-Positive Breast Cancer Treated in Accordance with the ACOSOG Z0011 Strategy.

Long-Term Survival Outcomes and Risk Factors for Axillary and Locoregional Recurrence in Japanese Patients with Sentinel Node-Positive Breast Cancer Treated in Accordance with the ACOSOG Z0011 Strategy.

Journal: Oncology

Published: February 01, 2024

Showing 1-8 of 8

Last Updated: 09/26/2026